MAPT and Alzheimer disease: The upregulation of COX-2 in the brains of AD patients contributes to tau hyperphosphorylation, amyloid-beta production, and increased proinflammatory cytokines and oxidative stress, leading to neuronal damage and cognitive decline [17].